AAAAAA

   
Results: 1-9 |
Results: 9
FEASIBILITY OF PRESCRIBING INJECTABLE HEROIN AND METHADONE TO OPIATE-DEPENDENT DRUG-USERS - ASSOCIATED HEALTH GAINS AND HARM REDUCTIONS
Authors: METREBIAN N SHANAHAN W WELLS B STIMSON GV
Citation: N. Metrebian et al., FEASIBILITY OF PRESCRIBING INJECTABLE HEROIN AND METHADONE TO OPIATE-DEPENDENT DRUG-USERS - ASSOCIATED HEALTH GAINS AND HARM REDUCTIONS, Medical journal of Australia, 168(12), 1998, pp. 596-600
ANTISENSE TO ICAM-1 (ISIS-9125) PREVENTS DEVELOPMENT OF INTESTINAL INFLAMMATION IN HLA-B27 TRANSGENIC RATS
Authors: BOWENYACYSHYN MB NATION N SHANAHAN W BENNETT F YACYSHYN BR
Citation: Mb. Bowenyacyshyn et al., ANTISENSE TO ICAM-1 (ISIS-9125) PREVENTS DEVELOPMENT OF INTESTINAL INFLAMMATION IN HLA-B27 TRANSGENIC RATS, Gastroenterology, 114(4), 1998, pp. 3850-3850
ANTISENSE TO ICAM-1 AFFECTS THE PERIPHERAL-BLOOD EXPRESSION AND INTESTINAL EXPRESSION OF ADHESION MOLECULES IN CROHNS-DISEASE
Authors: BOWENYACYSHYN MB SHANAHAN W BENNETT F TAMI J GALLATIN M ROTHLEIN B MAINOLFI E JEWELL L YACYSHYN BR
Citation: Mb. Bowenyacyshyn et al., ANTISENSE TO ICAM-1 AFFECTS THE PERIPHERAL-BLOOD EXPRESSION AND INTESTINAL EXPRESSION OF ADHESION MOLECULES IN CROHNS-DISEASE, Gastroenterology, 114(4), 1998, pp. 3851-3851
SAFETY OF RETREATMENT WITH ANTISENSE TO ICAM-1 (ISIS-2302) IN PATIENTS WITH STEROID-DEPENDENT CROHNS-DISEASE
Authors: YACYSHYN BR BOWENYACYSHYN MB TAMI J SAHBA B SHANAHAN W
Citation: Br. Yacyshyn et al., SAFETY OF RETREATMENT WITH ANTISENSE TO ICAM-1 (ISIS-2302) IN PATIENTS WITH STEROID-DEPENDENT CROHNS-DISEASE, Gastroenterology, 114(4), 1998, pp. 4574-4574
PHARMACOKINETIC PROPERTIES OF PHOSPHOROTHIOATE OLIGONUCLEOTIDES
Authors: LEEDS JM GEARY RS HENRY SP GLOVER J SHANAHAN W FITCHETT J BURCKIN T TRUONG L LEVIN AA
Citation: Jm. Leeds et al., PHARMACOKINETIC PROPERTIES OF PHOSPHOROTHIOATE OLIGONUCLEOTIDES, Nucleosides & nucleotides, 16(7-9), 1997, pp. 1689-1693
EFFICACY AND SAFETY OF ISIS-2302 (ICAM-I ANTISENSE OLIGONUCLEOTIDE) TREATMENT OF STEROID-DEPENDENT CROHNS-DISEASE
Authors: YACYSHYN B WOLOSCHUK B YACYSHYN MB MARTINI D DOAN K TAMI J BENNETT F KISNER D SHANAHAN W
Citation: B. Yacyshyn et al., EFFICACY AND SAFETY OF ISIS-2302 (ICAM-I ANTISENSE OLIGONUCLEOTIDE) TREATMENT OF STEROID-DEPENDENT CROHNS-DISEASE, Gastroenterology, 112(4), 1997, pp. 1123-1123
WHO SHOULD COLLECT OPIATE TREATMENT INDEX DATA IN OPIATE TREATMENT OUTCOME MONITORING - CLINIC STAFF OR RESEARCHERS
Authors: ADELEKAN M METREBIAN N TALLACK F STIMSON GV SHANAHAN W
Citation: M. Adelekan et al., WHO SHOULD COLLECT OPIATE TREATMENT INDEX DATA IN OPIATE TREATMENT OUTCOME MONITORING - CLINIC STAFF OR RESEARCHERS, Drug and alcohol review, 15(1), 1996, pp. 65-71
REPS EXPLAINED
Authors: SHANAHAN W
Citation: W. Shanahan, REPS EXPLAINED, Irish veterinary journal, 49(6), 1996, pp. 375-376
PHASE-1 STUDY OF AN ICAM-1 ANTISENSE OLIGONUCLEOTIDE (ISIS-2302)
Authors: SHANAHAN W GLOVER J MANT T AMIN D LEEDS J ZUCKERMAN J LEVIN A
Citation: W. Shanahan et al., PHASE-1 STUDY OF AN ICAM-1 ANTISENSE OLIGONUCLEOTIDE (ISIS-2302), Clinical pharmacology and therapeutics, 59(2), 1996, pp. 80-80
Risultati: 1-9 |